Maintenance therapy in newly diagnosed multiple myeloma: current recommendations

被引:4
|
作者
Brioli, Annamaria [1 ]
Tacchetti, Paola [1 ]
Zamagni, Elena [1 ]
Cavo, Michele [1 ]
机构
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
关键词
multiple myeloma; thalidomide; lenalidomide; bortezomib; maintenance; STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; PHASE-III; CONSOLIDATION THERAPY; INDUCTION THERAPY; INTERGROUPE FRANCOPHONE; THALIDOMIDE MAINTENANCE;
D O I
10.1586/14737140.2014.884930
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The recent availability of novel agents has substantially improved the outcomes of patients with Multiple Myeloma (MM). Achieving the deepest level of complete response and maintaining a sustained remission are important steps towards MM cure. To achieve this goal, consolidation and maintenance therapies are currently incorporated into the modern therapeutic paradigm. The excellent activity shown by new drugs has led to their investigational use as maintenance therapy. However, despite promising results of continuous treatment with the novel agents, consensus regarding maintenance therapy still lacks. This review will focus on maintenance therapy, offering an overview of the different strategies available in MM. The issue of continuous treatment in the light of new biological discoveries, including intra-clonal heterogeneity, will also be addressed.
引用
收藏
页码:581 / 594
页数:14
相关论文
共 50 条
  • [1] Maintenance Therapy for Multiple Myeloma
    McCarthy, Philip L.
    Palumbo, Antonio
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (05) : 839 - +
  • [2] Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival
    Palumbo, Antonio
    Attal, Michel
    Roussel, Murielle
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1253 - 1263
  • [3] Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma
    Brioli, Annamaria
    Kaiser, Martin F.
    Pawlyn, Charlotte
    Wu, Ping
    Gregory, Walter M.
    Owen, Roger
    Ross, Fiona M.
    Jackson, Graham H.
    Cavo, Michele
    Davies, Faith E.
    Morgan, Gareth J.
    LEUKEMIA & LYMPHOMA, 2013, 54 (09) : 1975 - 1981
  • [4] Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Moreau, Philippe
    Giralt, Sergio A.
    LEUKEMIA RESEARCH, 2012, 36 : S13 - S18
  • [5] Continuous treatment with new agents for newly diagnosed multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Lu, Hongkai
    Yu, Jinming
    ANTI-CANCER DRUGS, 2013, 24 (05) : 527 - 533
  • [6] Quadruplets, Maintenance, and More: The Future of Therapy for Newly Diagnosed Multiple Myeloma
    Krishnan, Amrita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S159 - S160
  • [7] Maintenance therapy in multiple myeloma
    Mewawalla, Prerna
    Chilkulwar, Abhishek
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (02) : 71 - 79
  • [8] Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents
    Nathwani, Nitya
    Larsen, Jeremy T.
    Kapoor, Prashant
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 127 - 136
  • [9] Current and future perspectives of maintenance therapy in multiple myeloma
    Nagarajan, Chandramouli
    Tan, Melinda S.
    Chen, Yunxin
    Martinelli, Giovanni
    Cerchione, Claudio
    PANMINERVA MEDICA, 2020, 62 (04) : 225 - 233
  • [10] Treatment of newly diagnosed multiple myeloma: advances in current therapy
    Kumar, Shaji
    MEDICAL ONCOLOGY, 2010, 27 : 14 - 24